Acumen Pharmaceuticals, Inc. ABOS
Set alert
0.21 USD -2.08 -90.83%
At close
0.22 +0.01 +4.66%
Pre-market · Nov 2, 6:04 AM ET
0.21 Day range 0.352
0.209 52-week range 3.60
- YTD
- -90.04%
- 1 year
- -90.54%
- Open
- 0.3394
- Prev close
- 2.29
- Mkt cap
- 15.20M
- Vol
- 68.11M
- Avg vol
- 1.56M
- EPS
- -1.55
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.21
- High
- 0.352
- Forward P/E
- -1.17
- Beta
- 0.04
- Short ratio
- 6.61
- Inst. own
- 78.46%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 2.48
- 200-d avg
- 2.89
- 1y target
- 10.80
5Y chart
Events in this range
- Mar 26, 2024Earnings: —; estimate -0.29; surprise —%
- May 14, 2024Earnings: -0.25; estimate -0.23; surprise -8.7%
- May 14, 2024Earnings: —; estimate -0.23; surprise —%
- May 15, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Jul 25, 2024Rating: Citigroup · — → Buy
- Aug 13, 2024Earnings: —; estimate -0.28; surprise —%
- Aug 13, 2024Earnings: -0.34; estimate -0.28; surprise -21.43%
- Aug 14, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Aug 15, 2024Rating: UBS · Buy → Buy
- Oct 3, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 12, 2024Earnings: -0.5; estimate -0.36; surprise -38.89%
- Nov 13, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (98)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 21, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 25, 2026 | 5 months ago |
| SMA: Bullish | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 6, 2026 | 7 months ago |
| SMA: Bearish | Mar 23, 2026 | 7 months ago |
| RSI: Overbought | Feb 23, 2026 | 8 months ago |
| MACD: Buy Signal | Jan 26, 2026 | 9 months ago |
| SMA: Bullish | Jan 19, 2026 | 9 months ago |
| SMA: Bearish | Jan 5, 2026 | 10 months ago |
| MACD: Sell Signal | Jan 5, 2026 | 10 months ago |
| SMA: Bullish | Dec 8, 2025 | 10 months ago |
| SMA: Bearish | Nov 10, 2025 | 11 months ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| SMA: Bearish | Sep 8, 2025 | 1 year ago |
| SMA: Bullish | Sep 1, 2025 | 1 year ago |
| SMA: Bearish | Aug 25, 2025 | 1 year ago |
| SMA: Bullish | Jul 7, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 21, 2025 | 1 year ago |
| RSI: Oversold | Apr 14, 2025 | 1 year ago |
| RSI: Oversold | Mar 31, 2025 | 1 year ago |
| MACD: Sell Signal | Dec 2, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bullish | Oct 21, 2024 | 2 years ago |
| SMA: Bullish | Oct 14, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 14, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 30, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 9, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 2, 2024 | 2 years ago |
| SMA: Bearish | Aug 26, 2024 | 2 years ago |
| SMA: Bullish | Aug 19, 2024 | 2 years ago |
| SMA: Bearish | Aug 5, 2024 | 2 years ago |
| SMA: Bearish | Jul 29, 2024 | 2 years ago |
| SMA: Bullish | Jul 22, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 22, 2024 | 2 years ago |
| SMA: Bullish | Jul 15, 2024 | 2 years ago |
| SMA: Bearish | May 27, 2024 | 2 years ago |
| MACD: Sell Signal | May 20, 2024 | 2 years ago |
| MACD: Buy Signal | May 13, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 22, 2024 | 2 years ago |
| SMA: Bearish | Apr 15, 2024 | 2 years ago |
| SMA: Bearish | Apr 8, 2024 | 2 years ago |
| SMA: Bullish | Feb 26, 2024 | 2 years ago |
| SMA: Bullish | Feb 19, 2024 | 2 years ago |
| SMA: Bearish | Jan 22, 2024 | 2 years ago |
| MACD: Buy Signal | Dec 25, 2023 | 2 years ago |
| SMA: Bullish | Dec 11, 2023 | 2 years ago |
| RSI: Oversold | Oct 23, 2023 | 3 years ago |
| SMA: Bearish | Sep 18, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 11, 2023 | 3 years ago |
| SMA: Bullish | Jul 10, 2023 | 3 years ago |
| SMA: Bullish | Jul 3, 2023 | 3 years ago |
| SMA: Bearish | Jun 26, 2023 | 3 years ago |
| SMA: Bearish | Jun 26, 2023 | 3 years ago |
| SMA: Bullish | Jun 12, 2023 | 3 years ago |
| SMA: Bearish | May 22, 2023 | 3 years ago |
| SMA: Bullish | May 8, 2023 | 3 years ago |
| MACD: Buy Signal | May 8, 2023 | 3 years ago |
| SMA: Bullish | May 1, 2023 | 3 years ago |
| SMA: Bearish | Feb 13, 2023 | 3 years ago |
| SMA: Bullish | Jan 30, 2023 | 3 years ago |
| SMA: Bearish | Jan 16, 2023 | 3 years ago |
| SMA: Bearish | Jan 16, 2023 | 3 years ago |
| SMA: Bullish | Jan 9, 2023 | 3 years ago |
| SMA: Bullish | Jan 9, 2023 | 3 years ago |
| SMA: Bearish | Dec 12, 2022 | 3 years ago |
| SMA: Bullish | Dec 5, 2022 | 3 years ago |
| SMA: Bearish | Nov 28, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 14, 2022 | 3 years ago |
| SMA: Bearish | Oct 31, 2022 | 4 years ago |
| SMA: Bullish | Sep 26, 2022 | 4 years ago |
| SMA: Bullish | Sep 26, 2022 | 4 years ago |
| SMA: Bearish | Sep 19, 2022 | 4 years ago |
| SMA: Bearish | Sep 12, 2022 | 4 years ago |
| SMA: Bullish | Aug 22, 2022 | 4 years ago |
| SMA: Bearish | Aug 15, 2022 | 4 years ago |
| SMA: Bullish | Jul 4, 2022 | 4 years ago |
| SMA: Bullish | Jun 20, 2022 | 4 years ago |
| SMA: Bearish | Jun 13, 2022 | 4 years ago |
| SMA: Bullish | Jun 6, 2022 | 4 years ago |
| SMA: Bearish | Mar 21, 2022 | 4 years ago |
| SMA: Bullish | Mar 7, 2022 | 4 years ago |
| SMA: Bullish | Feb 14, 2022 | 4 years ago |
Key statistics
- Market cap
- 107.54M
- Enterprise value
- -59.21M
- Trailing P/E
- 0.00
- Forward P/E
- -1.17
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.50
- EPS (TTM)
- -1.38
- Beta
- 0.04
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -41.69M
- Total cash
- 200.34M
- Total debt
- 29.99M
- Return on equity
- -32.83%
- Shares outstanding
- 60.08M
- Short % of float
- 3.10%
- 50-day average
- 2.48
- 200-day average
- 2.89
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 10.80 +5040.4% upside
Now 0.2101
- Target (low)
- 6.00
- Target (mean)
- 10.80
- Target (high)
- 15.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.36582.
Financials — quick view
ABOS Revenue — quarterly 0
ABOS Net income — quarterly -25.37M
ABOS EPS — quarterly -0.35
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.36 | -0.50 | -0.14 | -38.89% |
| Aug 13, 2024 | Jun 1, 2024 | -0.28 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | -0.28 | -0.34 | -0.06 | -21.43% |
| May 14, 2024 | Mar 1, 2024 | -0.23 | -0.25 | -0.02 | -8.70% |
| May 14, 2024 | Mar 1, 2024 | -0.23 | — | — | — |
| Mar 26, 2024 | Dec 1, 2023 | -0.29 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2024 | UBS | main | Buy | Buy |
| Aug 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 25, 2024 | Citigroup | init | — | Buy |
| May 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- acumenpharm.com
News
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Citigroup Downgrades Acumen Pharmaceuticals to Neutral, Lowers Price Target to $1
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Nasdaq Down Over 600 Points; Amazon Shares Fall Following Weak Q3 Results
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Acumen Pharma Says ALTITUDE-AD Missed Primary, Key Secondary Endpoints In Alzheimer's Study; Co. To Cease Clinical Development Of Sabirnetug, Preserve Cash And Explore Strategic Options
- Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer's Disease; Trial Did Not Meet Primary Endpoint
- Acumen Pharmaceuticals: A Speculative Buy Ahead Of November's Alzheimer's Readout
- Acumen Pharmaceuticals, Inc. (ABOS) Q3 2026 Earnings Call Transcript
- Acumen Pharmaceuticals Q3 Earnings Call Highlights
Your note
Sign in to keep a note on ABOS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARTON RUSSELL | Chief Operating Officer | Sale | Jan 17, 2024 | 96,867 |
| IVES JEFFREY L | Director | Sale | Aug 16, 2023 | 0 |
| MEISNER DEREK M | Officer | Sale | Jan 18, 2024 | 108,867 |
| O'CONNELL DANIEL JOSEPH | Chief Executive Officer | Sale | Jan 18, 2024 | 502,485 |
| RA CAPITAL MANAGEMENT, L.P. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Jul 20, 2023 | 0 |
| SIEMERS ERIC M.D. | Officer | Sale | Jan 17, 2024 | 117,576 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 24.85% | 14,932,063 | 26.73M | Sep 29, 2024 |
| Franklin Resources, Inc. | 5.91% | 3,549,069 | 6.35M | Sep 29, 2024 |
| Sands Capital Ventures, LLC | 5.69% | 3,417,075 | 6.12M | Sep 29, 2024 |
| Blackrock Inc. | 3.88% | 2,331,530 | 4.17M | Sep 29, 2024 |
| Rock Springs Capital Management, LP | 3.83% | 2,300,059 | 4.12M | Sep 29, 2024 |
| FMR, LLC | 3.38% | 2,028,117 | 3.63M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Strategic Series-Franklin Small Cap Growth Fund | 2.00% | 1,200,300 | 2.15M | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.91% | 1,146,316 | 2.05M | Sep 29, 2024 |
| Fidelity Select Portfolios - Health Care | 1.90% | 1,140,000 | 2.04M | Oct 30, 2024 |
| iShares Russell 2000 ETF | 1.68% | 1,009,063 | 1.81M | Oct 30, 2024 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 1.38% | 826,400 | 1.48M | Jul 30, 2024 |
| Fidelity Advisor Health Care Fund | 1.17% | 700,000 | 1.25M | Oct 30, 2024 |